APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mammalian Biopharmaceutical Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mammalian Biopharmaceutical Service Market Outlook and Growth Opportunities 2026

12 August 2026209 pages

Choose your research edition.

Industry ResearchMammalian Biopharmaceutical Service Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Mammalian Biopharmaceutical Service Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Mammalian Biopharmaceutical Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mammalian Biopharmaceutical Service Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Mammalian Biopharmaceutical Service Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Mammalian Biopharmaceutical Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mammalian Biopharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mammalian Biopharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mammalian Biopharmaceutical Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mammalian Biopharmaceutical Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mammalian Biopharmaceutical Service market include Novartis, KBI Biopharma, 3P Biopharmaceuticals, Sartorius Stedim Biotech, Merck Millipore, Rentschler Biopharma SE, Northway Biotech, Cambrex and Samsung Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Mammalian Biopharmaceutical Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mammalian Biopharmaceutical Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mammalian Biopharmaceutical Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Mammalian Biopharmaceutical Service market.

Mammalian Biopharmaceutical Service Segment by Company

Novartis

KBI Biopharma

3P Biopharmaceuticals

Sartorius Stedim Biotech

Merck Millipore

Rentschler Biopharma SE

Northway Biotech

Cambrex

Samsung Biologics

FUJIFILM Diosynth Biotechnologies

GBI

Thermo Fisher Scientific

Catalent

WuXi Biologics

Boehringer Ingelheim BioXcellence

Lonza

Abzena

AGC Biologics

Mammalian Biopharmaceutical Service Segment by Type

Cell Line Development

Analytical Testing

Technology Transfer

Formulation Development

Others

Mammalian Biopharmaceutical Service Segment by Application

Pharmaceutical

Contract Research Organizations (CROs)

Academic and Research Institutes

Biotechnology Companies

Government Agencies

Mammalian Biopharmaceutical Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mammalian Biopharmaceutical Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Mammalian Biopharmaceutical Service key companies, revenue, market share, and recent developments.

3. To split the Mammalian Biopharmaceutical Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Mammalian Biopharmaceutical Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mammalian Biopharmaceutical Service significant trends, drivers, influence factors in global and regions.

6. To analyze Mammalian Biopharmaceutical Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mammalian Biopharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mammalian Biopharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mammalian Biopharmaceutical Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mammalian Biopharmaceutical Service industry.

Chapter 3: Detailed analysis of Mammalian Biopharmaceutical Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Mammalian Biopharmaceutical Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Mammalian Biopharmaceutical Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mammalian Biopharmaceutical Service Industry Trends Table 2. Mammalian Biopharmaceutical Service Industry Drivers Table 3. Mammalian Biopharmaceutical Service Industry Opportunities and Challenges Table 4. Mammalian Biopharmaceutical Service Industry Restraints Table 5. Global Mammalian Biopharmaceutical Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mammalian Biopharmaceutical Service Revenue Share by Company (2021-2026) Table 7. Global Mammalian Biopharmaceutical Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Mammalian Biopharmaceutical Service Key Company Manufacturing Base & Headquarters Table 9. Global Mammalian Biopharmaceutical Service Company, Product Type & Application Table 10. Global Mammalian Biopharmaceutical Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Mammalian Biopharmaceutical Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cell Line Development Table 15. Significant Companies of Analytical Testing Table 16. Significant Companies of Technology Transfer Table 17. Significant Companies of Formulation Development Table 18. Significant Companies of Others Table 19. Global Mammalian Biopharmaceutical Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Mammalian Biopharmaceutical Service Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Mammalian Biopharmaceutical Service Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Mammalian Biopharmaceutical Service Sales Value Share by Type (2021-2026) Table 23. Global Mammalian Biopharmaceutical Service Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Pharmaceutical Table 25. Significant Companies of Contract Research Organizations (CROs) Table 26. Significant Companies of Academic and Research Institutes Table 27. Significant Companies of Biotechnology Companies Table 28. Significant Companies of Government Agencies Table 29. Global Mammalian Biopharmaceutical Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Mammalian Biopharmaceutical Service Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Mammalian Biopharmaceutical Service Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Mammalian Biopharmaceutical Service Sales Value Share by Application (2021-2026) Table 33. Global Mammalian Biopharmaceutical Service Sales Value Share by Application (2027-2032) Table 34. Global Mammalian Biopharmaceutical Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Mammalian Biopharmaceutical Service Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Mammalian Biopharmaceutical Service Sales Value Share by Region (2021-2026) Table 37. Global Mammalian Biopharmaceutical Service Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Mammalian Biopharmaceutical Service Sales Value Share by Region (2027-2032) Table 39. Global Mammalian Biopharmaceutical Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Mammalian Biopharmaceutical Service Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Mammalian Biopharmaceutical Service Sales Value Market Share by Country (2021-2026) Table 42. Global Mammalian Biopharmaceutical Service Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Mammalian Biopharmaceutical Service Sales Value Market Share by Country (2027-2032) Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis Mammalian Biopharmaceutical Service Product Portfolio Table 48. Novartis Recent Development Table 49. KBI Biopharma Company Information Table 50. KBI Biopharma Business Overview Table 51. KBI Biopharma Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. KBI Biopharma Mammalian Biopharmaceutical Service Product Portfolio Table 53. KBI Biopharma Recent Development Table 54. 3P Biopharmaceuticals Company Information Table 55. 3P Biopharmaceuticals Business Overview Table 56. 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Product Portfolio Table 58. 3P Biopharmaceuticals Recent Development Table 59. Sartorius Stedim Biotech Company Information Table 60. Sartorius Stedim Biotech Business Overview Table 61. Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Product Portfolio Table 63. Sartorius Stedim Biotech Recent Development Table 64. Merck Millipore Company Information Table 65. Merck Millipore Business Overview Table 66. Merck Millipore Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Merck Millipore Mammalian Biopharmaceutical Service Product Portfolio Table 68. Merck Millipore Recent Development Table 69. Rentschler Biopharma SE Company Information Table 70. Rentschler Biopharma SE Business Overview Table 71. Rentschler Biopharma SE Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Rentschler Biopharma SE Mammalian Biopharmaceutical Service Product Portfolio Table 73. Rentschler Biopharma SE Recent Development Table 74. Northway Biotech Company Information Table 75. Northway Biotech Business Overview Table 76. Northway Biotech Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Northway Biotech Mammalian Biopharmaceutical Service Product Portfolio Table 78. Northway Biotech Recent Development Table 79. Cambrex Company Information Table 80. Cambrex Business Overview Table 81. Cambrex Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Cambrex Mammalian Biopharmaceutical Service Product Portfolio Table 83. Cambrex Recent Development Table 84. Samsung Biologics Company Information Table 85. Samsung Biologics Business Overview Table 86. Samsung Biologics Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Samsung Biologics Mammalian Biopharmaceutical Service Product Portfolio Table 88. Samsung Biologics Recent Development Table 89. FUJIFILM Diosynth Biotechnologies Company Information Table 90. FUJIFILM Diosynth Biotechnologies Business Overview Table 91. FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Product Portfolio Table 93. FUJIFILM Diosynth Biotechnologies Recent Development Table 94. GBI Company Information Table 95. GBI Business Overview Table 96. GBI Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. GBI Mammalian Biopharmaceutical Service Product Portfolio Table 98. GBI Recent Development Table 99. Thermo Fisher Scientific Company Information Table 100. Thermo Fisher Scientific Business Overview Table 101. Thermo Fisher Scientific Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Thermo Fisher Scientific Mammalian Biopharmaceutical Service Product Portfolio Table 103. Thermo Fisher Scientific Recent Development Table 104. Catalent Company Information Table 105. Catalent Business Overview Table 106. Catalent Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Catalent Mammalian Biopharmaceutical Service Product Portfolio Table 108. Catalent Recent Development Table 109. WuXi Biologics Company Information Table 110. WuXi Biologics Business Overview Table 111. WuXi Biologics Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. WuXi Biologics Mammalian Biopharmaceutical Service Product Portfolio Table 113. WuXi Biologics Recent Development Table 114. Boehringer Ingelheim BioXcellence Company Information Table 115. Boehringer Ingelheim BioXcellence Business Overview Table 116. Boehringer Ingelheim BioXcellence Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. Boehringer Ingelheim BioXcellence Mammalian Biopharmaceutical Service Product Portfolio Table 118. Boehringer Ingelheim BioXcellence Recent Development Table 119. Lonza Company Information Table 120. Lonza Business Overview Table 121. Lonza Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. Lonza Mammalian Biopharmaceutical Service Product Portfolio Table 123. Lonza Recent Development Table 124. Abzena Company Information Table 125. Abzena Business Overview Table 126. Abzena Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Abzena Mammalian Biopharmaceutical Service Product Portfolio Table 128. Abzena Recent Development Table 129. AGC Biologics Company Information Table 130. AGC Biologics Business Overview Table 131. AGC Biologics Mammalian Biopharmaceutical Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. AGC Biologics Mammalian Biopharmaceutical Service Product Portfolio Table 133. AGC Biologics Recent Development Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Mammalian Biopharmaceutical Service Product Image Figure 2. Global Mammalian Biopharmaceutical Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mammalian Biopharmaceutical Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Mammalian Biopharmaceutical Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cell Line Development Image Figure 8. Analytical Testing Image Figure 9. Technology Transfer Image Figure 10. Formulation Development Image Figure 11. Others Image Figure 12. Global Mammalian Biopharmaceutical Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Mammalian Biopharmaceutical Service Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Mammalian Biopharmaceutical Service Sales Value Share by Type (2021-2032) Figure 15. Pharmaceutical Image Figure 16. Contract Research Organizations (CROs) Image Figure 17. Academic and Research Institutes Image Figure 18. Biotechnology Companies Image Figure 19. Government Agencies Image Figure 20. Global Mammalian Biopharmaceutical Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Mammalian Biopharmaceutical Service Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Mammalian Biopharmaceutical Service Sales Value Share by Application (2021-2032) Figure 23. Global Mammalian Biopharmaceutical Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Mammalian Biopharmaceutical Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Mammalian Biopharmaceutical Service Sales Value (2021-2032) & (US$ Million) Figure 26. North America Mammalian Biopharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Mammalian Biopharmaceutical Service Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Mammalian Biopharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Mammalian Biopharmaceutical Service Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Mammalian Biopharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Mammalian Biopharmaceutical Service Sales Value (2021-2032) & (US$ Million) Figure 32. South America Mammalian Biopharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Mammalian Biopharmaceutical Service Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Mammalian Biopharmaceutical Service Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Cell Line Development
  • Analytical Testing
  • Technology Transfer
  • Formulation Development
  • Others
Applications
  • Pharmaceutical
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes
  • Biotechnology Companies
  • Government Agencies
Companies covered
  • Novartis
  • KBI Biopharma
  • 3P Biopharmaceuticals
  • Sartorius Stedim Biotech
  • Merck Millipore
  • Rentschler Biopharma SE
  • Northway Biotech
  • Cambrex
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • GBI
  • Thermo Fisher Scientific
  • Catalent
  • WuXi Biologics
  • Boehringer Ingelheim BioXcellence
  • Lonza
  • Abzena
  • AGC Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mammalian Biopharmaceutical Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mammalian Biopharmaceutical Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Mammalian Biopharmaceutical Service Market Dynamics
  1. 2.1 Mammalian Biopharmaceutical Service Industry Trends
  2. 2.2 Mammalian Biopharmaceutical Service Industry Drivers
  3. 2.3 Mammalian Biopharmaceutical Service Industry Opportunities and Challenges
  4. 2.4 Mammalian Biopharmaceutical Service Industry Restraints
3 Mammalian Biopharmaceutical Service Market by Company
  1. 3.1 Global Mammalian Biopharmaceutical Service Company Revenue Ranking in 2025
  2. 3.2 Global Mammalian Biopharmaceutical Service Revenue by Company (2021-2026)
  3. 3.3 Global Mammalian Biopharmaceutical Service Company Ranking (2024-2026)
  4. 3.4 Global Mammalian Biopharmaceutical Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Mammalian Biopharmaceutical Service Company Product Type and Application
  6. 3.6 Global Mammalian Biopharmaceutical Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Mammalian Biopharmaceutical Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Mammalian Biopharmaceutical Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Mammalian Biopharmaceutical Service Market by Type
  1. 4.1 Mammalian Biopharmaceutical Service Type Introduction
  2. 4.1.1 Cell Line Development
  3. 4.1.2 Analytical Testing
  4. 4.1.3 Technology Transfer
  5. 4.1.4 Formulation Development
  6. 4.1.5 Others
  7. 4.2 Global Mammalian Biopharmaceutical Service Sales Value by Type
  8. 4.2.1 Global Mammalian Biopharmaceutical Service Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Mammalian Biopharmaceutical Service Sales Value by Type (2021-2032)
  10. 4.2.3 Global Mammalian Biopharmaceutical Service Sales Value Share by Type (2021-2032)
5 Mammalian Biopharmaceutical Service Market by Application
  1. 5.1 Mammalian Biopharmaceutical Service Application Introduction
  2. 5.1.1 Pharmaceutical
  3. 5.1.2 Contract Research Organizations (CROs)
  4. 5.1.3 Academic and Research Institutes
  5. 5.1.4 Biotechnology Companies
  6. 5.1.5 Government Agencies
  7. 5.2 Global Mammalian Biopharmaceutical Service Sales Value by Application
  8. 5.2.1 Global Mammalian Biopharmaceutical Service Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Mammalian Biopharmaceutical Service Sales Value by Application (2021-2032)
  10. 5.2.3 Global Mammalian Biopharmaceutical Service Sales Value Share by Application (2021-2032)
6 Mammalian Biopharmaceutical Service Regional Value Analysis
  1. 6.1 Global Mammalian Biopharmaceutical Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mammalian Biopharmaceutical Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Mammalian Biopharmaceutical Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Mammalian Biopharmaceutical Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mammalian Biopharmaceutical Service Sales Value (2021-2032)
  7. 6.3.2 North America Mammalian Biopharmaceutical Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Mammalian Biopharmaceutical Service Sales Value (2021-2032)
  10. 6.4.2 Europe Mammalian Biopharmaceutical Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Mammalian Biopharmaceutical Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Mammalian Biopharmaceutical Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Mammalian Biopharmaceutical Service Sales Value (2021-2032)
  16. 6.6.2 South America Mammalian Biopharmaceutical Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Mammalian Biopharmaceutical Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Mammalian Biopharmaceutical Service Sales Value Share by Country, 2025 VS 2032
7 Mammalian Biopharmaceutical Service Country-level Value Analysis
  1. 7.1 Global Mammalian Biopharmaceutical Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mammalian Biopharmaceutical Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Mammalian Biopharmaceutical Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Mammalian Biopharmaceutical Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Mammalian Biopharmaceutical Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Mammalian Biopharmaceutical Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Mammalian Biopharmaceutical Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Mammalian Biopharmaceutical Service Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 KBI Biopharma
  8. 8.2.1 KBI Biopharma Company Information
  9. 8.2.2 KBI Biopharma Business Overview
  10. 8.2.3 KBI Biopharma Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 KBI Biopharma Mammalian Biopharmaceutical Service Product Portfolio
  12. 8.2.5 KBI Biopharma Recent Developments
  13. 8.3 3P Biopharmaceuticals
  14. 8.3.1 3P Biopharmaceuticals Company Information
  15. 8.3.2 3P Biopharmaceuticals Business Overview
  16. 8.3.3 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 3P Biopharmaceuticals Mammalian Biopharmaceutical Service Product Portfolio
  18. 8.3.5 3P Biopharmaceuticals Recent Developments
  19. 8.4 Sartorius Stedim Biotech
  20. 8.4.1 Sartorius Stedim Biotech Company Information
  21. 8.4.2 Sartorius Stedim Biotech Business Overview
  22. 8.4.3 Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sartorius Stedim Biotech Mammalian Biopharmaceutical Service Product Portfolio
  24. 8.4.5 Sartorius Stedim Biotech Recent Developments
  25. 8.5 Merck Millipore
  26. 8.5.1 Merck Millipore Company Information
  27. 8.5.2 Merck Millipore Business Overview
  28. 8.5.3 Merck Millipore Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Millipore Mammalian Biopharmaceutical Service Product Portfolio
  30. 8.5.5 Merck Millipore Recent Developments
  31. 8.6 Rentschler Biopharma SE
  32. 8.6.1 Rentschler Biopharma SE Company Information
  33. 8.6.2 Rentschler Biopharma SE Business Overview
  34. 8.6.3 Rentschler Biopharma SE Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Rentschler Biopharma SE Mammalian Biopharmaceutical Service Product Portfolio
  36. 8.6.5 Rentschler Biopharma SE Recent Developments
  37. 8.7 Northway Biotech
  38. 8.7.1 Northway Biotech Company Information
  39. 8.7.2 Northway Biotech Business Overview
  40. 8.7.3 Northway Biotech Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Northway Biotech Mammalian Biopharmaceutical Service Product Portfolio
  42. 8.7.5 Northway Biotech Recent Developments
  43. 8.8 Cambrex
  44. 8.8.1 Cambrex Company Information
  45. 8.8.2 Cambrex Business Overview
  46. 8.8.3 Cambrex Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cambrex Mammalian Biopharmaceutical Service Product Portfolio
  48. 8.8.5 Cambrex Recent Developments
  49. 8.9 Samsung Biologics
  50. 8.9.1 Samsung Biologics Company Information
  51. 8.9.2 Samsung Biologics Business Overview
  52. 8.9.3 Samsung Biologics Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Samsung Biologics Mammalian Biopharmaceutical Service Product Portfolio
  54. 8.9.5 Samsung Biologics Recent Developments
  55. 8.10 FUJIFILM Diosynth Biotechnologies
  56. 8.10.1 FUJIFILM Diosynth Biotechnologies Company Information
  57. 8.10.2 FUJIFILM Diosynth Biotechnologies Business Overview
  58. 8.10.3 FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FUJIFILM Diosynth Biotechnologies Mammalian Biopharmaceutical Service Product Portfolio
  60. 8.10.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  61. 8.11 GBI
  62. 8.11.1 GBI Company Information
  63. 8.11.2 GBI Business Overview
  64. 8.11.3 GBI Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GBI Mammalian Biopharmaceutical Service Product Portfolio
  66. 8.11.5 GBI Recent Developments
  67. 8.12 Thermo Fisher Scientific
  68. 8.12.1 Thermo Fisher Scientific Company Information
  69. 8.12.2 Thermo Fisher Scientific Business Overview
  70. 8.12.3 Thermo Fisher Scientific Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Thermo Fisher Scientific Mammalian Biopharmaceutical Service Product Portfolio
  72. 8.12.5 Thermo Fisher Scientific Recent Developments
  73. 8.13 Catalent
  74. 8.13.1 Catalent Company Information
  75. 8.13.2 Catalent Business Overview
  76. 8.13.3 Catalent Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Catalent Mammalian Biopharmaceutical Service Product Portfolio
  78. 8.13.5 Catalent Recent Developments
  79. 8.14 WuXi Biologics
  80. 8.14.1 WuXi Biologics Company Information
  81. 8.14.2 WuXi Biologics Business Overview
  82. 8.14.3 WuXi Biologics Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 WuXi Biologics Mammalian Biopharmaceutical Service Product Portfolio
  84. 8.14.5 WuXi Biologics Recent Developments
  85. 8.15 Boehringer Ingelheim BioXcellence
  86. 8.15.1 Boehringer Ingelheim BioXcellence Company Information
  87. 8.15.2 Boehringer Ingelheim BioXcellence Business Overview
  88. 8.15.3 Boehringer Ingelheim BioXcellence Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim BioXcellence Mammalian Biopharmaceutical Service Product Portfolio
  90. 8.15.5 Boehringer Ingelheim BioXcellence Recent Developments
  91. 8.16 Lonza
  92. 8.16.1 Lonza Company Information
  93. 8.16.2 Lonza Business Overview
  94. 8.16.3 Lonza Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Lonza Mammalian Biopharmaceutical Service Product Portfolio
  96. 8.16.5 Lonza Recent Developments
  97. 8.17 Abzena
  98. 8.17.1 Abzena Company Information
  99. 8.17.2 Abzena Business Overview
  100. 8.17.3 Abzena Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Abzena Mammalian Biopharmaceutical Service Product Portfolio
  102. 8.17.5 Abzena Recent Developments
  103. 8.18 AGC Biologics
  104. 8.18.1 AGC Biologics Company Information
  105. 8.18.2 AGC Biologics Business Overview
  106. 8.18.3 AGC Biologics Mammalian Biopharmaceutical Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 AGC Biologics Mammalian Biopharmaceutical Service Product Portfolio
  108. 8.18.5 AGC Biologics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst